Long Non-Coding RNAs in Allergy

过敏中的长非编码 RNA

基本信息

  • 批准号:
    10363445
  • 负责人:
  • 金额:
    $ 18.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-23 至 2022-01-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The overall goal of this proposal is to identify fundamental mechanisms controlling allergic responses by the long non-coding RNA (lncRNA) Morrbid. Type 2 allergic responses are characterized by the generation of CD4+ T helper type 2 (Th2) cells, and the recently identified IL-13+ T follicular helper (Tfh13) cells, which drive production of high-affinity anaphylactic IgE. Given their central role in allergy, understanding how T cells are programmed to become Th2 and Tfh13 cells could allow manipulation of T cell responses to mitigate allergy. Recent work has revealed a critical function for lncRNAs in immunity, opening up an exciting area of research that may uncover new targets and pathways for therapeutic intervention. lncRNAs do not encode proteins; rather, many produce functional RNA transcripts that are powerful regulators of cellular identity, function and survival. Our preliminary data show that the lncRNA Morrbid controls CD4+ T cell function and is required for type 2 immune responses in vivo. Single-cell RNA-sequencing (scRNA-Seq) of CD4+ T cells revealed Morrbid to be most highly expressed in Il13-expressing Th2 and Tfh13 cells, and Tfh13 cells are reduced during type 2 responses in Morrbid-/- mice. Our hypothesis is that Morrbid is an epigenetic regulator of Th2 and Tfh13 differentiation during allergic responses. In Aim 1 we will identify cell types that require Morrbid to generate type 2 immune responses. Using mice with a conditional Morrbid allele crossed to different Cre-expressing lines, we will test the function of Morrbid in dendritic cells, B cells, T cells, and Tfh cells during type 2 responses in vivo. We will analyze expression of human MORRBID in T cells from donors with or without allergies using scRNA-Seq, to determine whether Th2 and Tfh cells overexpress MORRBID in allergy. Finally, using CRISPR/Cas9-based epigenome editing in primary human T cells, we will determine the impact of MORRBID silencing and overexpression on CD4+ T helper cell polarization in vitro. In Aim 2 we will dissect molecular mechanisms by which the Morrbid locus regulates gene expression in T cells. To this end we have developed a novel genetic targeting strategy based on pre-tRNA processing to ablate lncRNA transcripts without blocking transcription in vivo. In Aim 3 we will map the Morrbid interactome to determine how Morrbid controls T cell function. To identify genes directly bound by Morrbid, we will employ a novel method that allows simultaneous mapping of both lncRNA-chromatin interactions and lncRNA-associated chromatin loops genome-wide, called RNA ChIA-PET (RNA-Chromatin Interaction Analysis by Paired-End Tag sequencing). To identify regulatory proteins interacting with Morrbid, we will use RAP-MS (RNA Antisense Purification coupled with Mass Spectrometry). Through completion of these Aims, we will elucidate new regulatory pathways controlling type 2 immunity that could potentially be exploited to treat allergy. In addition, we will have established and validated two novel tools of significant benefit to the research community which suffers from a dearth of standard methodology for analyzing lncRNA function; a lncRNA-specific gene- targeting approach, and a method to map genome-wide lncRNA-associated chromosomal interactions.
项目摘要 这项建议的总体目标是确定长期控制过敏反应的基本机制, 非编码RNA(lncRNA)2型过敏反应的特征是产生CD 4 + T细胞, 辅助性2型(Th 2)细胞,以及最近鉴定的IL-13+滤泡辅助性T细胞(Tfh 13),其驱动生产 高亲和力过敏性IgE鉴于它们在过敏中的核心作用,了解T细胞如何编程 成为Th 2和Tfh 13细胞可以允许操纵T细胞应答以减轻过敏。最近的工作已经 揭示了lncRNA在免疫中的关键功能,开辟了一个令人兴奋的研究领域, 治疗干预的新目标和途径。lncRNA不编码蛋白质;相反,许多lncRNA产生 功能性RNA转录物是细胞身份、功能和存活的强大调节剂。我们的初步 数据显示lncRNA Morrbid控制CD 4 + T细胞功能,并且是2型免疫应答所需的 in vivo. CD 4 + T细胞的单细胞RNA测序(scRNA-Seq)显示Morrbid在CD 4 + T细胞中表达最高。 在表达IL 13的Th 2和Tfh 13细胞中,在Morrbid-/-小鼠的2型应答期间Tfh 13细胞减少。 我们的假设是,Morrbid是过敏反应过程中Th 2和Tfh 13分化的表观遗传调节因子。 应答在目标1中,我们将确定需要Morrbid产生2型免疫应答的细胞类型。使用 将条件性Morrbid等位基因与不同Cre表达系杂交的小鼠,我们将测试Morrbid的功能 在体内2型应答期间树突状细胞、B细胞、T细胞和Tfh细胞中。我们将分析 使用scRNA-Seq在来自具有或不具有过敏症的供体的T细胞中检测人MORBID,以确定Th 2 而Tfh细胞在变态反应中过表达MORBID。最后,使用基于CRISPR/Cas9的表观基因组编辑, 在人T细胞中,我们将确定MORBID沉默和过表达对CD 4 + T辅助细胞的影响, 体外极化。在目标2中,我们将剖析Morrbid位点调控基因的分子机制 在T细胞中的表达。为此,我们开发了一种基于前tRNA的新型遗传靶向策略 处理以消除lncRNA转录物而不阻断体内转录。在目标3中,我们将绘制Morrbid 相互作用组以确定Morrbid如何控制T细胞功能。为了识别与Morrbid直接结合的基因,我们 将采用一种新的方法,允许同时映射lncRNA-染色质相互作用, lncRNA相关的染色质环全基因组,称为RNA ChIA-PET(RNA-染色质相互作用分析 通过配对末端标签测序)。为了鉴定与Morrbid相互作用的调节蛋白,我们将使用RAP-MS (RNA反义纯化与质谱联用)。通过实现这些目标,我们将 阐明了控制2型免疫的新的调节途径,这些途径可能被用于治疗过敏。 此外,我们将建立并验证两个对研究界有重大益处的新工具 其缺乏分析lncRNA功能的标准方法; lncRNA特异性基因- 靶向方法,以及绘制全基因组lncRNA相关染色体相互作用的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM WILLIAMS其他文献

ADAM WILLIAMS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM WILLIAMS', 18)}}的其他基金

Long Non-Coding RNAs in Allergy
过敏中的长非编码 RNA
  • 批准号:
    10493379
  • 财政年份:
    2021
  • 资助金额:
    $ 18.94万
  • 项目类别:
Long Non-Coding RNAs in Allergy
过敏中的长非编码 RNA
  • 批准号:
    10555000
  • 财政年份:
    2021
  • 资助金额:
    $ 18.94万
  • 项目类别:
lncRNA Control of Airway Epithelial Cell Responses to Type 2 Inflammation
lncRNA 控制气道上皮细胞对 2 型炎症的反应
  • 批准号:
    10318082
  • 财政年份:
    2019
  • 资助金额:
    $ 18.94万
  • 项目类别:
lncRNA Control of Airway Epithelial Cell Responses to Type 2 Inflammation
lncRNA 控制气道上皮细胞对 2 型炎症的反应
  • 批准号:
    10555004
  • 财政年份:
    2019
  • 资助金额:
    $ 18.94万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 18.94万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了